SLC16A1 and cancer: Originally developed as an ALK and ROS1 inhibitor for the treatment of non‐small cell lung cancer (NSCLC) [39], the newfound ability of crizotinib to inhibit CD147 and MCT1 extends its therapeutic potential into the realm of cancer metabolic reprogramming.